{"id":3079,"date":"2025-03-05T16:45:40","date_gmt":"2025-03-05T13:45:40","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=3079"},"modified":"2025-03-07T12:54:07","modified_gmt":"2025-03-07T09:54:07","slug":"pepgen-temporarily-pauses-exon-51-skipping-study","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/de\/pepgen-temporarily-pauses-exon-51-skipping-study\/","title":{"rendered":"PepGen unterbricht vor\u00fcbergehend die Studie zum Skippen von Exon 51"},"content":{"rendered":"<p class=\"wp-block-paragraph\">PepGen, ein Biotechnologieunternehmen im klinischen Stadium, das die n\u00e4chste Generation von Oligonukleotidtherapien mit dem Ziel vorantreibt, die Behandlung schwerer neuromuskul\u00e4rer und neurologischer Erkrankungen zu ver\u00e4ndern, gab heute seine freiwillige Entscheidung bekannt, die Phase-2-Studie CONNECT2-EDO51 zu PGN-EDO51 bei Patienten mit Duchenne-Muskeldystrophie (DMD) vor\u00fcbergehend zu unterbrechen, bis das Unternehmen die Ergebnisse der 10-mg\/kg-Kohorte in der laufenden Phase-2-Studie CONNECT1-EDO51 pr\u00fcfen kann.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Die ersten beiden Kohorten der CONNECT1-Studie sind vollst\u00e4ndig eingeschrieben und Daten aus der 10 mg\/kg-Kohorte werden im dritten Quartal 2025 erwartet. Seit dem letzten Sicherheitsupdate des Unternehmens vom 23. Januar 2025 wurden keine neuen Sicherheitsprobleme im Zusammenhang mit PGN-EDO51 festgestellt.<\/p>","protected":false},"excerpt":{"rendered":"<p>PepGen, a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced its voluntary decision to temporarily pause the Phase 2 CONNECT2-EDO51 study of PGN-EDO51 in patients with Duchenne muscular dystrophy (DMD) until the Company can review results from the [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":3081,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[281],"tags":[137,275,122,193,194,77,273,274],"class_list":["post-3079","post","type-post","status-publish","format-standard","has-post-thumbnail","category-press-releases","tag-clinical-trial","tag-connect1-edo51","tag-exon-51","tag-exon-51-skipping","tag-exon-51-treatment","tag-exon-skipping","tag-pepgen","tag-pgn-edo51"],"_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/posts\/3079","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/comments?post=3079"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/posts\/3079\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/media\/3081"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/media?parent=3079"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/categories?post=3079"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/tags?post=3079"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}